Sherri-Ann Maryna Burnett, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteoporosis, Postmenopausal | 13 | 2022 | 396 | 2.290 |
Why?
|
Teriparatide | 13 | 2016 | 227 | 2.110 |
Why?
|
Vitamin D | 12 | 2023 | 3301 | 1.910 |
Why?
|
Bone Density | 27 | 2024 | 3551 | 1.820 |
Why?
|
Fractures, Bone | 10 | 2024 | 2046 | 1.370 |
Why?
|
Vitamin D Deficiency | 7 | 2021 | 1386 | 1.340 |
Why?
|
Bone Density Conservation Agents | 12 | 2016 | 795 | 1.340 |
Why?
|
Fibroblast Growth Factors | 5 | 2017 | 867 | 1.210 |
Why?
|
Phosphates | 5 | 2017 | 770 | 1.190 |
Why?
|
Osteoporosis | 8 | 2023 | 1605 | 1.070 |
Why?
|
Internship and Residency | 9 | 2024 | 5879 | 0.940 |
Why?
|
Body Composition | 6 | 2021 | 2422 | 0.900 |
Why?
|
Postmenopause | 6 | 2024 | 2513 | 0.860 |
Why?
|
Menopause | 9 | 2024 | 1646 | 0.860 |
Why?
|
Ergocalciferols | 2 | 2015 | 110 | 0.840 |
Why?
|
Biological Availability | 2 | 2021 | 390 | 0.790 |
Why?
|
Women's Health | 10 | 2024 | 2065 | 0.770 |
Why?
|
Testosterone | 7 | 2020 | 2472 | 0.740 |
Why?
|
Libido | 3 | 2020 | 119 | 0.710 |
Why?
|
Vitamin D-Binding Protein | 1 | 2021 | 131 | 0.700 |
Why?
|
Age Determination by Skeleton | 1 | 2018 | 126 | 0.570 |
Why?
|
Bone and Bones | 4 | 2021 | 2568 | 0.570 |
Why?
|
Bullying | 1 | 2020 | 232 | 0.560 |
Why?
|
Gender Identity | 1 | 2022 | 766 | 0.520 |
Why?
|
Aromatase Inhibitors | 3 | 2013 | 513 | 0.510 |
Why?
|
Metformin | 1 | 2023 | 906 | 0.510 |
Why?
|
Vitamins | 4 | 2022 | 1634 | 0.490 |
Why?
|
Anemia, Sickle Cell | 1 | 2023 | 1064 | 0.480 |
Why?
|
Estradiol | 5 | 2019 | 1937 | 0.480 |
Why?
|
Algorithms | 4 | 2024 | 14026 | 0.470 |
Why?
|
Dietary Supplements | 4 | 2019 | 3414 | 0.470 |
Why?
|
Goserelin | 3 | 2020 | 126 | 0.470 |
Why?
|
Nitriles | 2 | 2009 | 971 | 0.450 |
Why?
|
Language | 1 | 2023 | 1539 | 0.450 |
Why?
|
Triazoles | 2 | 2009 | 903 | 0.440 |
Why?
|
Medicine | 1 | 2021 | 941 | 0.410 |
Why?
|
Muscle Strength | 2 | 2013 | 624 | 0.410 |
Why?
|
Parathyroid Hormone | 5 | 2012 | 1803 | 0.410 |
Why?
|
Spine | 2 | 2018 | 1118 | 0.380 |
Why?
|
Hypogonadism | 2 | 2009 | 798 | 0.380 |
Why?
|
Leadership | 1 | 2020 | 1385 | 0.370 |
Why?
|
Emergency Medicine | 1 | 2020 | 1197 | 0.370 |
Why?
|
Radius | 3 | 2021 | 441 | 0.360 |
Why?
|
Advisory Committees | 2 | 2024 | 786 | 0.340 |
Why?
|
Seasons | 2 | 2012 | 1519 | 0.330 |
Why?
|
Calcitriol | 3 | 2023 | 296 | 0.320 |
Why?
|
Anti-Mullerian Hormone | 2 | 2022 | 407 | 0.310 |
Why?
|
Calcium | 4 | 2017 | 5727 | 0.310 |
Why?
|
Humans | 71 | 2024 | 761423 | 0.310 |
Why?
|
Osteoporotic Fractures | 2 | 2024 | 411 | 0.300 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2023 | 12143 | 0.300 |
Why?
|
Female | 47 | 2024 | 392581 | 0.270 |
Why?
|
Health | 1 | 2009 | 398 | 0.270 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2008 | 163 | 0.260 |
Why?
|
Alendronate | 4 | 2015 | 175 | 0.250 |
Why?
|
Menstrual Cycle | 2 | 2020 | 539 | 0.250 |
Why?
|
Mass Screening | 1 | 2021 | 5428 | 0.250 |
Why?
|
Curriculum | 3 | 2023 | 3741 | 0.250 |
Why?
|
Internal Medicine | 4 | 2024 | 1051 | 0.240 |
Why?
|
Diphosphonates | 1 | 2009 | 636 | 0.230 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7389 | 0.220 |
Why?
|
Furin | 1 | 2023 | 46 | 0.220 |
Why?
|
Perimenopause | 2 | 2017 | 142 | 0.220 |
Why?
|
Bone Resorption | 2 | 2018 | 723 | 0.210 |
Why?
|
Sex Factors | 3 | 2024 | 10548 | 0.210 |
Why?
|
Bone Remodeling | 5 | 2016 | 581 | 0.210 |
Why?
|
Drug Therapy, Combination | 7 | 2020 | 6309 | 0.210 |
Why?
|
Femur Neck | 4 | 2022 | 314 | 0.210 |
Why?
|
Middle Aged | 35 | 2024 | 220826 | 0.200 |
Why?
|
Faculty, Medical | 3 | 2024 | 1202 | 0.190 |
Why?
|
Hormones | 3 | 2017 | 869 | 0.190 |
Why?
|
Education | 1 | 2024 | 536 | 0.190 |
Why?
|
Insulin Resistance | 1 | 2015 | 3963 | 0.190 |
Why?
|
Hot Flashes | 1 | 2024 | 330 | 0.190 |
Why?
|
Thyrotropin | 1 | 2024 | 834 | 0.180 |
Why?
|
Education, Medical, Graduate | 5 | 2024 | 2374 | 0.180 |
Why?
|
Thyroxine | 1 | 2024 | 668 | 0.180 |
Why?
|
Insulin | 1 | 2015 | 6602 | 0.180 |
Why?
|
Renal Dialysis | 1 | 2010 | 1797 | 0.180 |
Why?
|
Chromatography, Affinity | 1 | 2021 | 532 | 0.170 |
Why?
|
Tibia | 2 | 2016 | 1070 | 0.170 |
Why?
|
Aggression | 1 | 2024 | 750 | 0.170 |
Why?
|
Hypothyroidism | 1 | 2024 | 667 | 0.170 |
Why?
|
Male | 27 | 2024 | 360736 | 0.160 |
Why?
|
Hip | 2 | 2021 | 255 | 0.160 |
Why?
|
Collagen Type I | 4 | 2016 | 616 | 0.160 |
Why?
|
Longitudinal Studies | 6 | 2024 | 14599 | 0.160 |
Why?
|
Cross-Sectional Studies | 6 | 2023 | 26112 | 0.160 |
Why?
|
Aged | 21 | 2024 | 169235 | 0.150 |
Why?
|
Bone Diseases, Metabolic | 1 | 2022 | 409 | 0.150 |
Why?
|
Clinical Competence | 5 | 2024 | 4793 | 0.150 |
Why?
|
Asymptomatic Diseases | 1 | 2021 | 587 | 0.150 |
Why?
|
Adult | 21 | 2024 | 221148 | 0.150 |
Why?
|
Kidney Failure, Chronic | 1 | 2010 | 2471 | 0.140 |
Why?
|
United States | 9 | 2024 | 72339 | 0.140 |
Why?
|
Risk Assessment | 5 | 2024 | 23990 | 0.140 |
Why?
|
Attitude | 1 | 2022 | 775 | 0.140 |
Why?
|
Physicians, Women | 1 | 2023 | 508 | 0.140 |
Why?
|
Eunuchism | 1 | 2016 | 19 | 0.130 |
Why?
|
Immunoassay | 2 | 2012 | 746 | 0.130 |
Why?
|
Patient Preference | 1 | 2023 | 924 | 0.130 |
Why?
|
25-Hydroxyvitamin D 2 | 1 | 2015 | 40 | 0.130 |
Why?
|
Burnout, Professional | 1 | 2024 | 704 | 0.130 |
Why?
|
Physicians | 2 | 2024 | 4591 | 0.130 |
Why?
|
Minerals | 1 | 2017 | 283 | 0.130 |
Why?
|
Reproduction | 1 | 2020 | 645 | 0.130 |
Why?
|
Risk Factors | 7 | 2024 | 74167 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 20556 | 0.120 |
Why?
|
Calcifediol | 1 | 2015 | 161 | 0.120 |
Why?
|
Neoplasms | 1 | 2023 | 22164 | 0.110 |
Why?
|
Body Fat Distribution | 2 | 2020 | 245 | 0.110 |
Why?
|
Double-Blind Method | 4 | 2015 | 12330 | 0.110 |
Why?
|
Puberty | 1 | 2017 | 501 | 0.110 |
Why?
|
Diet | 3 | 2018 | 8074 | 0.110 |
Why?
|
Drug Substitution | 1 | 2015 | 290 | 0.100 |
Why?
|
Lumbar Vertebrae | 3 | 2022 | 1881 | 0.100 |
Why?
|
Absorptiometry, Photon | 2 | 2016 | 1737 | 0.100 |
Why?
|
Societies, Medical | 1 | 2024 | 3905 | 0.100 |
Why?
|
Single-Blind Method | 1 | 2015 | 1571 | 0.100 |
Why?
|
Adipose Tissue | 2 | 2021 | 3312 | 0.090 |
Why?
|
Hypoparathyroidism | 1 | 2012 | 136 | 0.090 |
Why?
|
Boston | 2 | 2015 | 9330 | 0.090 |
Why?
|
Retinoid X Receptors | 1 | 2010 | 91 | 0.090 |
Why?
|
Adiposity | 1 | 2020 | 1877 | 0.090 |
Why?
|
Peptides | 4 | 2016 | 4345 | 0.090 |
Why?
|
Follow-Up Studies | 5 | 2022 | 39117 | 0.090 |
Why?
|
Rickets | 1 | 2010 | 70 | 0.090 |
Why?
|
Risk | 3 | 2019 | 9612 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2023 | 7825 | 0.080 |
Why?
|
Hypoalbuminemia | 1 | 2010 | 86 | 0.080 |
Why?
|
Obesity | 2 | 2023 | 12938 | 0.080 |
Why?
|
Drug Resistance | 1 | 2015 | 1595 | 0.080 |
Why?
|
Blood Glucose | 1 | 2023 | 6391 | 0.080 |
Why?
|
Young Adult | 7 | 2016 | 59207 | 0.080 |
Why?
|
Procollagen | 3 | 2016 | 187 | 0.080 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2008 | 174 | 0.080 |
Why?
|
Decision Trees | 1 | 2010 | 504 | 0.080 |
Why?
|
Chromatography, Liquid | 1 | 2012 | 983 | 0.080 |
Why?
|
Receptors, Calcitriol | 1 | 2010 | 360 | 0.070 |
Why?
|
Up-Regulation | 1 | 2017 | 4124 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12058 | 0.070 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4852 | 0.070 |
Why?
|
Parathyroid Neoplasms | 1 | 2008 | 242 | 0.070 |
Why?
|
Cognition | 1 | 2024 | 6986 | 0.070 |
Why?
|
Aging | 2 | 2020 | 8705 | 0.070 |
Why?
|
Prospective Studies | 5 | 2022 | 54415 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2009 | 590 | 0.070 |
Why?
|
Logistic Models | 2 | 2012 | 13255 | 0.070 |
Why?
|
Adolescent | 5 | 2018 | 88313 | 0.070 |
Why?
|
Etidronic Acid | 1 | 2006 | 63 | 0.070 |
Why?
|
Educational Measurement | 2 | 2024 | 1254 | 0.070 |
Why?
|
Treatment Outcome | 9 | 2020 | 64651 | 0.070 |
Why?
|
Testis | 1 | 2009 | 794 | 0.070 |
Why?
|
Follicle Stimulating Hormone | 2 | 2019 | 726 | 0.070 |
Why?
|
Dinoprostone | 1 | 2009 | 597 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3357 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3418 | 0.060 |
Why?
|
Premenopause | 2 | 2022 | 1039 | 0.060 |
Why?
|
Tandem Mass Spectrometry | 1 | 2012 | 1188 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5335 | 0.060 |
Why?
|
Aged, 80 and over | 9 | 2020 | 58956 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15262 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 2218 | 0.060 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2022 | 4579 | 0.060 |
Why?
|
Age Factors | 2 | 2022 | 18400 | 0.060 |
Why?
|
Steroids | 1 | 2009 | 929 | 0.060 |
Why?
|
Body Mass Index | 3 | 2017 | 12951 | 0.060 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 1068 | 0.060 |
Why?
|
Vasomotor System | 1 | 2024 | 207 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2021 | 22168 | 0.050 |
Why?
|
Sweating | 1 | 2024 | 155 | 0.050 |
Why?
|
Competency-Based Education | 1 | 2024 | 222 | 0.050 |
Why?
|
Child | 4 | 2022 | 80162 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3810 | 0.050 |
Why?
|
Linear Models | 1 | 2012 | 5869 | 0.050 |
Why?
|
Prevalence | 2 | 2023 | 15717 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7049 | 0.050 |
Why?
|
Sodium | 1 | 2006 | 1588 | 0.050 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2023 | 855 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 29620 | 0.050 |
Why?
|
Penile Erection | 1 | 2020 | 100 | 0.040 |
Why?
|
Cohort Studies | 3 | 2024 | 41446 | 0.040 |
Why?
|
Gels | 1 | 2020 | 422 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2690 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2020 | 680 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 1 | 2008 | 2803 | 0.040 |
Why?
|
Administration, Cutaneous | 1 | 2020 | 713 | 0.040 |
Why?
|
Pregnanediol | 1 | 2017 | 18 | 0.040 |
Why?
|
Waist Circumference | 1 | 2021 | 934 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15498 | 0.040 |
Why?
|
Corpus Luteum | 1 | 2017 | 81 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15838 | 0.040 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2019 | 550 | 0.030 |
Why?
|
Estrone | 1 | 2017 | 234 | 0.030 |
Why?
|
Intra-Abdominal Fat | 1 | 2021 | 612 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2520 | 0.030 |
Why?
|
Body Weight | 1 | 2006 | 4618 | 0.030 |
Why?
|
Drug Combinations | 2 | 2013 | 2048 | 0.030 |
Why?
|
Cosmetics | 1 | 2016 | 102 | 0.030 |
Why?
|
Luteinizing Hormone | 1 | 2017 | 820 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 8000 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10766 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 11902 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2010 | 20093 | 0.020 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2016 | 841 | 0.020 |
Why?
|
Incidence | 2 | 2022 | 21341 | 0.020 |
Why?
|
Genetic Markers | 1 | 2016 | 2613 | 0.020 |
Why?
|
Time Factors | 1 | 2012 | 39975 | 0.020 |
Why?
|
Peptide Fragments | 2 | 2016 | 5115 | 0.020 |
Why?
|
Cell Line | 1 | 2023 | 15605 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1638 | 0.020 |
Why?
|
Retreatment | 1 | 2009 | 598 | 0.020 |
Why?
|
Smoking | 1 | 2023 | 9052 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2898 | 0.020 |
Why?
|
Osteocalcin | 1 | 2006 | 274 | 0.020 |
Why?
|
Animals | 2 | 2023 | 168441 | 0.020 |
Why?
|
Radiography | 1 | 2015 | 6966 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8641 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2023 | 17912 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8529 | 0.010 |
Why?
|
Femur | 1 | 2006 | 1307 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10498 | 0.010 |
Why?
|
Medication Adherence | 1 | 2009 | 2176 | 0.010 |
Why?
|
Mice | 1 | 2023 | 81509 | 0.010 |
Why?
|
Child, Preschool | 1 | 2012 | 42254 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2012 | 80582 | 0.000 |
Why?
|